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Abstract
Rheumatic diseases in women of childbearing years may necessitate
drug treatment during a pregnancy, to control maternal disease
activity and to ensure a successful pregnancy outcome. This
survey is based on a consensus workshop of international experts
discussing effects of anti-inflammatory, immunosuppressive and
biological drugs during pregnancy and lactation. In addition, effects
of these drugs on male and female fertility and possible long-term
effects on infants exposed to drugs antenatally are discussed
where data were available. Recommendations for drug treatment
during pregnancy and lactation are given.
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Introduction
The pregnancy categories of the United States Food and
Drug Administration (FDA) in their present form are often not
helpful for the clinician treating patients with active chronic
disease during pregnancy and lactation. They combine risk
assessment and benefit, and are for most products based on
animal data. There is no requirement to update categories
with human experience. Drug trials in pregnant or lactating
mothers are not performed with new drugs. Therefore the
only information on the safety of drugs during pregnancy and
lactation is derived from experimental and preclinical animal
studies. Human experience accumulates in most cases from
inadvertent drug exposure during pregnancy and lactation.
Because only drugs considered safe can be studied in
pregnant or lactating women, the number of controlled
studies is small. In the absence of controlled studies,
reporting bias favours the reporting of negative experiences,
particularly in case reports and small case series.
An important aspect of exposure in utero to drugs is possible
long-term effects that will become manifest later in life.
Because a follow-up several decades after antenatal
exposure is not easily performed, information on late harmful
effects in offspring is not available for most drugs. However,
as a result of increasing awareness, studies are planned or in
progress addressing these important questions.
Gonadotoxic effects of anti-inflammatory and immuno-
suppressive drugs have only seldom been studied except for
cytotoxic drugs and, in men, salazopyrine. However, there is
an increasing awareness among patients that drugs may
impair fertility or be mutagenic. Again, available information
concerns mostly experimental and preclinical animal studies.
Information on the excretion of drugs into breast milk is based
mostly on single-dose or short-term treatment. Studies
enrolling a large number of lactating women have not been
performed. The effect of the drug on the nursing infant has in
many cases not been studied. Investigations studying an
influence of chronic drug ingestion on child behaviour and
development are also lacking. In general, drug concentrations
in breast milk that expose the suckling infant to 0.1% of the
maternal dose are regarded as fairly safe, whereas an
ingestion of about 10% of the mother’s dose requires
caution. Recommendations given for drugs for which no
reports or only single case reports exist are based on
theoretical considerations. This is the case for many
immunosuppressive drugs and the biologicals. In view of the
substantial benefits of breastfeeding, denying it unnecessarily
is a serious concern.
Recommendations on prescribing during pregnancy differ,
sometimes considerably, in articles and textbooks. Even the
recommendations given by the producer of a given drug can
vary in different countries. This situation is unsatisfying for
both the patient and the treating physician.
For this reason an international workshop of experts with
experience in drug therapy of pregnant and lactating women
was arranged. The aim was to reach a consensus on anti-
inflammatory and immunosuppressive drugs during
pregnancy and lactation with a focus on patients with
rheumatic disease.
Methods
A panel of 29 international experts including 17 specialists of
internal medicine and rheumatology, 8 obstetricians, 3
paediatricians and 1 specialist in genetics agreed to
participate in a consensus workshop on antirheumatic drugs
during pregnancy and lactation held in connection with the
4th International Conference on Sex Hormones, Pregnancy
and Rheumatic Diseases, held in Stresa, Italy, on 20 to 22
September 2004. Four categories of drugs were discussed
in separate working groups: anti-inflammatory drugs,
corticosteroids, immunosuppressive drugs and biological
agents. Current practice of prescribing during pregnancy and
lactation was evaluated by questionnaires for the four drug
categories under discussion. The results of these
questionnaires revealed which issues needed special
attention because of diverging practice of the specialists.
Before the workshop, members of the four working groups
searched the databases Medline and Cochrane for the period
1960 to 2004 under the following terms: each drug, fertility,
gonadal toxicity, pregnancy, teratogenicity, lactation, and
children of mothers treated during pregnancy. Because of the
scarcity of data, all types of original observations in humans
were accepted provided they were published in English,
Italian, French, German or Spanish. It was acknowledged that
causality between observed fetal or neonatal effects and a
given drug was often not documented, and that the possibility
for chromosomal aberrations or effects of the underlying
maternal disease were frequently not taken into account in
published experience.
The data from the available scientific literature were
summarized in the form of surveys, which were sent to the
participants before the workshop. The data were then
presented and discussed in workshops devoted to the
above-mentioned groups of drugs. Finally the conclusions
and recommendations of the working groups were discussed
by all participants in a plenary session.
If no consensus could be reached for a given drug, the
reason for diverging opinions is stated in the
recommendations. Consensus was reached for most drugs.
When clinical evidence was lacking, consideration of legal
issues has necessitated recommendations based on
theoretical risks for several drugs. The level of evidence for
the recommendations are presented in accordance with the
classification by Miyakis and colleagues [1], as follows: Class
I is a prospective study in a broad spectrum of the
representative population or meta-analysis of randomized
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controlled trials; Class II is a prospective study in a narrow
spectrum of the representative population or well-designed
cohort or case-control analytic study or retrospective study in
a broad spectrum of the representative population; Class III is
a retrospective study in a narrow spectrum of the
representative population; and Class IV is a study design in
which predictor is not applied in a blinded fashion or a
descriptive case series or an expert opinion. The application
of this classification has its problems because, in the field of
drugs during pregnancy and lactation, randomized controlled
studies are simply a minority. As a result the level of evidence
for the teratogenicity of methotrexate and cyclophosphamide
is only III. The low level of evidence for drugs during
breastfeeding is likewise due to the scanty documentation
and total absence of controlled studies. In contrast, the
classification reveals the low level of evidence on which many
of the recommendations are based. This opens for clinical
decisions weighing risk and benefit of therapy in the
individual patient.
Note
Data on breastfeeding or fertility are presented in the text only
when studied in humans. Otherwise the information is given
exclusively in the tables. With regard to biological drugs,
sufficient data on which to base recommendations exist only
for etanercept and infliximab. Other biological drugs are
therefore not included in this survey.
Non-steroidal anti-inflammatory drugs (NSAID)
NSAID and outcome of pregnancy
A Danish case-control study showed a link between the use
of NSAID during pregnancy and miscarriage [2]. Odds ratios
ranged from 1.3 for NSAID use 10 to 12 weeks before
miscarriage to 7.0 for use 1 week before miscarriage.
Potential bias and confounders of the study were the validity
of the registry variables, confounding by indication for
treatment, and the fact that prescription and not drug
consumption had been recorded [3]. A second population-
based cohort study including 1,063 women confirmed an
increased risk of miscarriage for the use of NSAID (including
aspirin) but not of paracetamol during pregnancy [4]. The
odds ratio (OR) was 1.8, but increased to 5.6 when taken
around conception and to 8.1 when used for more than
1 week. Interference of NSAID with implantation and
placental circulation was suspected as the explanation for the
findings. By contrast, a meta-analysis of low-dose aspirin
during the first trimester did not find an increase in
miscarriage [5]. The risk for miscarriage did not differ
between women treated with aspirin or placebo (relative risk
(RR) 0.92; 95% confidence interval (CI) 0.71 to 119).
By stimulating uterine contractions and enhancing cervical
ripening, prostaglandins are important mediators in
parturition. Inhibitors of cyclo-oxygenases (COX) can prolong
gestation and labour. Indomethacin, aspirin, ibuprofen,
sulindac, diclofenac and ketoprofen [6-8] as well as the
preferential COX-2 inhibitors nimesulide and meloxicam [8,9]
have been used successfully for the inhibition of premature
labour. Similarly, celecoxib has been found to be as effective
as indomethacin as a tocolytic agent [10].
Potential mutagenic and teratogenic effects
Animal studies
In rats and rabbits, the incidence of diaphragmatic hernia,
ventricular septum defect and gastroschisis/midline defects
is increased in fetuses exposed to NSAID when compared
with non-exposed controls [11,12]. The incidences of the
three defects are higher in aspirin-treated animals than in
non-aspirin NSAID-treated animals. This indicates that
irreversible inhibition of COX-1 and COX-2 is more toxic than
reversible inhibition. It was also shown that inhibition of COX-
1 mediates these developmental anomalies [12].
Human studies
Several population-based cohort and case-control studies
have assessed the teratogenic risks of first-trimester use of
non-selective COX inhibitors, including aspirin. Neither the
American Collaborative Perinatal Project [13,14], the
Michigan Medicaid surveillance study [15], the Swedish
National Project [16], nor the recent Danish population-based
study [3] together comprising several hundred thousand
pregnancies have found an increased risk of congenital
malformations. First-trimester use of selective COX-2
inhibitors has not been reported in human pregnancy.
A meta-analysis of published reports on use of aspirin (doses
not specified) during the first trimester found no increased
risk for congenital anomalies including renal anomalies and
congenital heart defects. However, a significantly higher risk
of gastroschisis was detected in infants born to women using
aspirin in the first trimester compared with non-aspirin users
(OR 2.37; 95% CI 1.44 to 3.88) [17]. The Spanish
Collaborative study of Congenital Malformations confirmed
an increased risk of gastroschisis at first-trimester prenatal
exposure to salicylates (OR 3.47, p = 0.015) after controlling
for maternal age and maternal smoking in a case-control
study [18].
Effects on the ductus arteriosus
Both COX-1 and COX-2 are expressed in endothelial and
smooth muscle cells of the ductus arteriosus [19] and hence
the constriction or premature closure of the ductus is a risk
with all NSAID. No constriction of the ductus arteriosus
occurred in the only human study of 12 pregnancies exposed
to celecoxib [10]. Effects on ductal blood flow have been
shown for most of the non-selective COX inhibitors occurring
as early as 4 hours after administration of the drug [20,21].
Several studies with fetal echocardiography found an
increasing rate of constriction of the ductus arteriosus from 0
before gestational week 27 to 43% in the period 27 to
30 weeks of gestation and 61% between 31 to 34 weeks of
gestation during treatment with indomethacin independently
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of the fetal serum concentration [22-24]. The constriction
frequently reversed within 24 to 48 hours after the cessation
of therapy. However, several studies have shown a significant
association between pulmonary hypertension in newborn
infants and antenatal exposure to aspirin, naproxen or
ibuprofen in the third trimester. The severity of pulmonary
hypertension was dose related [24,25].
Effects on fetal and neonatal renal function
COX-1 is expressed in renal tubuli and COX-2 in renal
medulla [19]. The blockade of prostaglandin synthesis by
NSAID and the decreased activation of prostaglandin
receptors cause reduced renal perfusion and oligo-
hydramnios. Adverse effects on fetal renal function have been
reported for non-selective and selective COX inhibitors
[24,26-28]. A marked decline in fetal urine output has been
observed within 5 hours of indomethacin ingestion, and
oligohydramnios developed in 70 to 82% of pregnancies
during the first week of treatment, but disappeared after
discontinuation of the drug. Development of oligohydramnios
has been shown to be dose dependent [26]. Short-term
treatment with celecoxib reduced fetal urine production, but
less than indomethacin [10]. Transient anuria, but also fatal
persistent anuria and irreversible end-stage renal failure, has
been reported in newborn infants exposed to indomethacin or
nimesulide [27-29].
Other fetal/neonatal effects
High-dose aspirin and indomethacin given close to delivery
have been shown to cause bleeding tendencies and
haemorrhage in the central nervous system in the newborn
infant [24,30]. Clotting abnormalities have also been
detected in newborn infants exposed to 325 to 650 mg of
aspirin within 1 week before delivery [15].
Low-dose aspirin (LDA)
Adverse effects of LDA (less than 325 mg/day) on pregnancy
outcome were studied in a meta-analysis [5]. Women who
took aspirin had a significantly lower risk of preterm delivery
than did those treated with placebo (RR 0.92; 95% CI 0.86
to 0.98). There was no significant difference in perinatal
mortality (RR 0.92; 95% CI 0.81 to 1.05) and in the rate of
small-for-gestational-age infants (12 studies; RR 0.96; 95%
CI 0.87 to 1.07) among offspring of mothers treated with
aspirin and those of mothers treated with a placebo [5]. More
than 10,000 pregnancies exposed to aspirin at 60 to
80 mg/day during the second and third trimester up to term
have been reported without any increase in impaired renal
function, pulmonary hypertension or clotting ability of the
newborn infant [31]. Doppler investigation of fetuses aged 15
to 40 weeks exposed to 60 mg of aspirin daily during the
second and third trimesters did not reveal any effect on the
ductus arteriosus [32]. One study found that LDA (less than
100 mg) given to the mother could suppress platelet
thromboxane A2 formation in the newborn infant that
recovered within 2 days after discontinuation of the drug [33].
There are some reports on epidural haematoma in patients
who, while on LDA, underwent epidural anaesthesia;
however, prospective studies have not found an increased
risk for this complication [34].
Effects of NSAID on fertility
COX-1 and COX-2 are involved in ovulation and implantation
[34,35]. Several case reports and small series have
described transient infertility after treatment with non-aspirin
NSAIDs such as indomethacin, diclofenac, piroxicam and
naproxen [36-38]. Studies in animals and humans have
shown that NSAID can inhibit the rupture of the luteinized
follicle and thereby cause transient infertility. A prospective,
randomized trial of ibuprofen in 12 women detected a delay
of 2 days or more in follicle rupture in a small number of
treated women [38]. However, no alterations of serum
progesterone or luteinizing hormone levels were observed. In
a study of 13 healthy women, 6 of whom were given the
selective COX-2 inhibitor rofecoxib, delayed follicle rupture
was observed in 4 of them [39].
A study of men attending an infertility clinic found a decrease
in sperm count and quality in non-prescription, chronic users
of NSAID (mostly aspirin) at low or moderate doses [40].
Breastfeeding
Most NSAID are excreted in very small quantities into human
breast milk [41,42]. The American Academy of Pediatrics
(AAP) considers flufenamic acid, ibuprofen, indomethacin,
diclofenac, mefenamic acid, naproxen, piroxicam and tolmetin
to be compatible with breastfeeding [43]. Aspirin at more
than 100 mg/day should be used cautiously because of
potential adverse effects in the nursing infant [43]. Feeding
immediately before a dose can help to minimize infant
exposure to NSAID.
Conclusion and recommendation (Tables 1 and 2)
• Non-selective and selective COX inhibitors can prevent or
retard ovulation. The frequency of ovulation inhibition is
unknown (evidence level IV).
• Non-selective COX inhibitors are not teratogenic and can
be continued during the first and second trimester
(evidence level I).
• At present there are no reliable data on selective COX-2
inhibitors; they should therefore be avoided during
pregnancy (evidence level IV).
• After gestational week 20, all NSAID (except aspirin at
less than 100 mg/day) can cause constriction of the
ductus arteriosus and impair fetal renal function (evidence
level I).
• All NSAID except LDA should be withdrawn at gestational
week 32 (evidence level IV).
• There is no consensus on when to stop LDA before
delivery. Some advise cessation of LDA treatment 1 week
before a planned delivery with epidural anaesthesia
(evidence level IV). Other experts do not stop LDA in
Arthritis Research & Therapy    Vol 8 No 3 Østensen et al.
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pregnant patients with antiphospholipid syndrome,
regarding the benefit of LDA as being greater than the
small risk of haematoma connected with epidural
anaesthesia (evidence level II).
• Breastfeeding immediately before a dose can help to
minimize infant exposure to NSAID (evidence level IV).
New anticoagulant drugs
Currently, the most widely used drugs for treatment and
secondary prevention of thromboembolic manifestations and
pregnancy morbidity caused by antiphospholipid syndrome
are LDA, heparin (unfractionated or of low molecular mass)
and oral anticoagulants. Their optimal use in pregnant
patients with APS has been described [44,45].
Current developments target potent drugs with a predictable
mode of action, easy mode of administration and minimal
requirements for blood control. For platelet inhibition, effective
oral preparations that directly block the glycoprotein IIb/IIIa
receptor on platelets (the binding site for fibrinogen) are to be
expected on the market soon [46]. Pentasaccharides, which
are molecules that induce a conformational change in the
antithrombin molecule so that this can bind and inactivate
activated coagulation factor X, are logical alternatives for low-
molecular-mass heparin. The pentasaccharide fondoparinux
can be administered once daily subcutaneously in a fixed
dose and has proven efficacy for the treatment and
prophylaxis of venous thromboembolic manifestations
[47,48]. Fondoparinux crosses the placenta, and cord blood
samples contain levels about one-tenth of those in maternal
blood [49]. Ximegalatran is a derivate from hirudin, a direct
thrombin inhibitor, that can be given orally in two fixed daily
doses, does not need monitoring and is at least as effective
as conventional treatment in non-valvular atrial fibrillation [50]
and for the treatment and prophylaxis of venous thrombo-
embolic events [51,52]. Its effect is not influenced by food,
Available online http://arthritis-research.com/content/8/3/209
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Table 1
Effect of non-steroidal anti-inflammatory drugs, glucocorticosteroids and bisphosphonates on human pregnancy and fertility
Long-term Impairment 
FDA Transplacental Human effects in of 
Drug riska passage teratogenicity Fetal/neonatal adverse effects offspring fertility
Non-steroidal B/D Yes No In late pregnancy, constriction of the ductus Not studied Cases of 
anti-inflammatory arteriosus, reduction of renal blood flow inhibition of 
drugs follicle rupture
Prednisone B Limited Increase in Rare (cataract, adrenal insufficiency, infection) Not studied Not studied
oral clefts
Dexamethasone C Yes Not reportedb Neurodevelopmental abnormalities Not studied Not studied
Betamethasone C Yes Not reportedb Neurodevelopmental abnormalities ? Not studied Not studied
Bisphosphonates C Not Not reported Two cases of hypocalcaemia in the 
studied newborn infant Not studied Not studied
Details and references are given in the text. aThe United States Food and Drug Administration (FDA) pregnancy risk categories are as follows: A,
no risk in controlled clinical studies in humans; B, human data reassuring or when absent, animal studies show no risk; C, human data are lacking;
animal studies show risk or are not done; D, positive evidence of risk, benefit may outweigh; X, contraindicated during pregnancy. bNo indication for
maternal use in the first trimester.
Table 2
Non-steroidal anti-inflammatory drugs, corticosteroids and bisphosphonates during lactation
Drug Secretion into breast milk Effect on nursing infant Breastfeeding allowed
Non-steroidal In low concentrations No adverse effects Diclofenac, flufenamic acid, ibuprofen, 
anti-inflammatory drugs indomethacin, ketorolac, mefenamic 
acid, naproxen and piroxicam are 
compatible with breastfeeding [41-43]
Prednisone 0.025% of maternal dose No adverse effects Compatible with breastfeeding [84,85]
Dexamethasone Not studied Not known Avoid
Betamethasone Not studied Not known Avoid
Bisphosphonates Pamidronate not detected, no No adverse effect in one case [91] Insufficient data. Risk-benefit must be 
reports on other bisphosphonates weighed before breastfeeding
drugs or P450 enzymes. Because of hepatic toxicity,
however, it has not been approved by the FDA. Currently,
little is known about the safety of the new anticoagulants
during pregnancy and lactation.
Conclusion and recommendation
• At the present state of knowledge, the new antiplatelet
and anticoagulant drugs cannot be recommended for use
in pregnant or lactating women. The pentasaccharide
fondoparinux can cross the placenta, suggesting that it is
less safe than heparin or low-molecular-mass heparin
during pregnancy (evidence level IV).
Corticosteroids
11β-Hydroxysteroid dehydrogenase in the placenta converts
cortisol and corticosterone to the relatively inactive 11-keto
forms, leaving no more than 10% of the active drug to reach
the fetus [53]. Glucocorticoids with fluorine at the 9α
position, like betamethasone and dexamethasone, are
considerably less well metabolized by the placenta.
Side effects with special relevance to pregnancy
Corticosteroid side effects in pregnant women include all that
are present in non-pregnant subjects taking corticosteroids.
Side effects such as increased blood pressure, osteopenia,
osteonecrosis and susceptibility to infection are of special
relevance in pregnancy. Pregnancy induces insulin resistance
at later stages, and the resulting glucose intolerance is further
enhanced by exogenous glucocorticoids with an increased
risk of gestational diabetes. Pregnancy-specific complications
are premature rupture of the membranes, frequently reported
in corticosteroid-treated patients with systemic lupus
erythematosus (SLE) and in one controlled study comparing
treatment with corticosteroids with treatment with heparin in
pregnant antiphospholipid-antibody-positive patients [54].
Potential mutagenic and teratogenic effects
Hydrocortisone produces dose-related teratogenic and toxic
effects in genetically susceptible experimental animals, with
increased rates of cleft palate, cataract, fetal loss and fetal
growth restriction [55,56].
In the human, results from case-control and prospective
studies indicate that exposure to hydrocortisone and
prednisone during the first trimester can lead to a small
increase in oral clefts [57-61]. A meta-analysis found a 3.3-
fold increased OR of oral clefts after first-trimester exposure
to corticosteroids [62]. Similar results were reported by the
Spanish Collaborative Study of Congenital Malformations
[57] and by two additional studies [59,61], but a reporting
bias might exist because several large studies found no
statistically increased rate of oral clefts [60,63]. Available
data do not allow a conclusion to be drawn about the specific
oral cleft phenotype associated with glucocorticoid exposure
in humans (cleft lip, cleft palate or both). Since oral clefts
occur at about 1:1,000 births in the general population, the
possible increase to 3 or 4 for every 1,000 births after
embryonic exposure to corticosteroids is minimal [62]. On the
whole, corticosteroids do not seem to increase the risk of
congenital abnormalities noticeably in humans.
The influence of corticosteroids on intrauterine growth has
been controversial. Some authors have demonstrated an
increased incidence of low-birthweight babies in mothers on
corticosteroids [56,64], whereas others have not [65].
Infections in newborn infants after antepartum exposure to
corticosteroids occur rather infrequently [66] and maternal
corticosteroid therapy does not induce general immuno-
suppression in the newborn infant [67]. The possible
induction of hypertension in adult life by antenatal exposure to
corticosteroids has not been proven in humans [68]. Other
rare adverse events reported for antenatal exposure to
corticosteroids are neonatal cataract [69] and adrenal
suppression in children born to women taking high doses of
steroids during pregnancy [70,71].
Antenatal exposure to synthetic fluorinated
corticosteroids betamethasone and dexamethasone
A single course of fluorinated corticosteroids (betamethasone
or dexamethasone, 24 mg) to pregnant women at risk for
preterm delivery, between 24 and 34 weeks of gestational
age, clearly reduced the risk of death, respiratory distress
syndrome and cerebral haemorrhage in their preterm infants
[72]. In the meantime, however, evidence has accumulated
on the potential harm of repeated courses of steroids for the
mother and the fetus. Findings in animals widely suggest that
repeated antenatal steroid doses can interfere with the
growth and development of the immature brain [73,74], and
observations on humans suggest that antenatal and postnatal
dexamethasone may negatively affect the child’s neuro-
psychological development [75-78]. In view of this concern, a
further NIH consensus conference in 2000 confirmed the
previous statement of the advantages of one course of
antenatal corticosteroids but also made it clear that, in view
of their potential hazard, repeated courses should not be
given routinely but be reserved for patients in randomized
controlled clinical trials [79].
The possible negative effects seem linked more to
dexamethasone than to betamethasone [80]. In addition, a
separate meta-analysis of the data in the Cochrane review
showed that only betamethasone, and not dexamethasone,
significantly reduces neonatal mortality [81]. For these two
reasons it has been suggested that betamethasone should
be preferred when available [82]. Adverse effects on
neuropsychological development in children have not been
observed after exposure to steroids that are inactivated by
placental enzymes [83].
Breastfeeding
Only trace amounts of hydrocortisone are excreted into
human breast milk [84]. In six lactating women, prednisolone
Arthritis Research & Therapy    Vol 8 No 3 Østensen et al.
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doses of 10 to 80 mg/day resulted in milk concentrations
ranging from 5% to 25% of maternal serum levels [85]. Even
at a maternal dose of 80 mg/day, the nursing infant would
ingest only 10 µg/kg which corresponds to <10% of the
infant’s endogenous cortisol production. No data are
available for dexamethasone or betamethasone in lactating
women [43].
Conclusion and recommendation (Tables 1 and 2)
• Maternal indications: prednisone, prednisolone and
methyl prednisolone.
• Fluorinated corticosteroids for antenatal treatment:
betamethasone should be preferred when available rather
than dexamethasone (evidence level II).
• Stress doses of hydrocortisone at delivery are recommen-
ded in patients on long-term therapy (evidence level IV).
• Corticosteroids do not seem to increase the risk of
congenital abnormalities noticeably in humans (evidence
level II).
• In case of in utero exposure to fluorinated steroids,
consider postnatal steroids for the baby only if adrenal
insufficiency is documented (neonatologist advice is
warranted) (evidence level IV).
• Breastfeeding is allowed with moderate doses of steroids
(evidence level II). At doses > 40 mg consider
breastfeeding timing 4 hours after the dose (evidence
level IV).
Osteoporosis prevention
For women treated either with corticosteroids or with heparin
throughout pregnancy, prevention of osteoporosis is
important [86]. Bisphosphonates accumulate in bone for long
periods. In mice and rats, gestational exposure to
bisphosphonates was associated with decreased fetal bone
growth and decreased fetal weight [87]. Three case reports
have described the use of bisphosphonates in pregnant
women. Two of the children born had transient hypo-
calcaemia, the third had normal laboratory values and
developed normally to 1 year of age [88-91].
• Because of insufficient data, pregnancy should be
postponed for 6 months after withdrawal of bisphospho-
nates (evidence level IV).
• The routine use of oral calcium and vitamin D
supplements is recommended in pregnancy and lactation
(evidence level IV).
Antimalarial drugs chloroquine (CQ) and
hydroxychloroquine (HCQ)
Potential mutagenic and teratogenic effects
CQ was embryotoxic and fetotoxic in high doses (250 to
1,500 mg/kg) in experimental animals. Eye malformations
occurred in 45% of animals at 1,000 mg/kg [92]. CQ
accumulated preferentially in melanin-containing structures in
the fetal uveal tract and inner ear when given during
pregnancy [92].
CQ and HCQ cross the placenta with no significant
difference in the mean concentration in maternal and cord
blood [93]. Weekly malaria prophylaxis with 300 mg of CQ
throughout gestation did not increase the congenital
malformation rate [94]. In the rheumatism literature, reports
on several hundred pregnancies exposed to CQ 250 mg
daily or HCQ 200 to 400 mg daily during the first trimester
did not find an increase in congenital malformations or
cardiac conduction disturbances in children exposed
antenatally to antimalarials [88,95-100]. Malformations of the
inner ear and other abnormalities after treatment with higher
than the recommended dose of CQ throughout pregnancy
were reported after intrauterine exposure to 500 mg daily of
CQ in three siblings born to a mother with SLE [101]. HCQ
has not been associated with congenital malformations.
Breastfeeding
Three studies examined the presence of CQ after the
administration of single doses (5 mg/kg and 600 mg) in
lactating women [100,102]. Daily ingestion of CQ by a
nursing child was calculated as 2.2 to 4.2% of the maternal
dose. Two case reports measured the secretion of HCQ
during lactation and found 0.35% and 0.0005% of the
maternal dose in human breast milk [103,104].
Long-term effects in children
Several studies have investigated long-term effects in
children exposed in utero or during lactation to HCQ. No
decrease in visual acuity, visual field or colour vision, or
alterations in electroretinogram and electro-oculogram or
hearing impairment, were detected in children studied during
the first year of life or up to 4 years of age [105-108]. A case-
control study of 133 pregnancies exposed to HCQ found no
visual, hearing, growth or developmental abnormalities in
children followed up for 108 months. Electrocardiograms of
exposed children were normal [99].
Conclusion and recommendation (Tables 3 and 4)
• When indicated, continue antimalarials during pregnancy
and lactation (evidence level II).
• HCQ is the antimalarial of choice in fertile women in need
of treatment (evidence level IV).
• CQ and HCQ are compatible with breastfeeding
(evidence level IV).
Sulphasalazine (SSZ)
Potential mutagenic and teratogenic effects
Reproduction studies with SSZ in rats and rabbits at doses
up to six times the human dose have not shown impaired
female fertility or harm to the fetus.
A population-based case-control study demonstrated no
significant increase in selected congenital abnormalities in
the children of women treated with SSZ during pregnancy
[109]. A national survey evaluated the outcome of
pregnancies associated with inflammatory bowel disease
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(IBD). In 186 pregnancies of women treated with SSZ alone
or with concomitant steroid therapy, the incidence of fetal
morbidity and mortality was comparable both with that of 245
untreated IBD pregnancies and with pregnancies in the
general population [110]. Additional studies of pregnancies
in women with IBD confirmed these results [111-114]. There
have been isolated reports on children born with congenital
malformations to mothers treated with SSZ during pregnancy
[115]. A study comparing fertility rates and fetal abnormalities
of patients with IBD with the general population found a
higher rate of malformations among offspring (particularly of
men) in patients treated with SSZ [115]. Because SSZ
inhibits the gastrointestinal and cellular uptake of folate, a
possible role of folate deficiency cannot be ruled out [116].
Some experts have advised the cessation of SSZ in the last
trimester, fearing it could displace bilirubin from albumin and
thus induce neonatal pathological jaundice. Yet the bilirubin-
displacing capacity of sulphapyridine and SSZ at the low
concentrations measured in cord blood is negligible [117].
Kernicterus in the newborn infant after exposure to SSZ in
utero has not been reported. Aplastic anaemia was found in
an aborted fetus exposed during the first trimester to SSZ
[118], and another case reported congenital severe
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Table 3
Effect of immunosuppressive, cytotoxic and biological drugs on human pregnancy and reproduction
Long-term Impairment 
FDA Transplacental Human effects in of 
Drug riska passage teratogenicity Fetal/neonatal adverse effects offspring fertility
Chloroquine/ C/C Yes No Not at recommended doses No impairment Not studied
hydroxychloroquine of vision or hearing
Sulphasalazine B Fetal like No Case reports of aplastic anaemia and Not studied In men: 
maternal serum neutropenia at >2g maternal dose oligospermia, 
concentration decreased 
sperm motility, 
abnormal forms
Leflunomide X No data Data not None published Not studied Not studied
conclusive
Azathioprine Db Yes No Sporadic congenital anomalies. Transient Normal immune No
Mercaptopurine immune alterations in newborn infants responses in 
childhood. One 
case report of late 
development of 
autoimmunity.
Methotrexate X Methotrexate + Yes Cytopenia None reported Oligospermia 
polyglutamates at high doses
Cyclophosphamide D Yes – animal data Yes Chromosomal abnormalities. Cytopenia Anecdotal In males 
and females
Cyclosporine C 10–50% of No Transient immune alterations None reported No
maternal plasma 
concentration
Tacrolimus C Yes Not reported Hyperkalaemia, renal impairment Not studied Not studied
Mycophenolate C Yes 3 reports of Not reported Not studied Not studied
mofetil congenital 
abnormalities
Intravenous C Yes No No fetal effects reported Not studied Not studied
immunoglobulin
Etanercept B Yes Not reported Not reported Not studied Not studied
Infliximab B Not Not reported Not reported Not studied Data not 
reported conclusive
Details and references are given in the text. aThe United States Food and Drug Administration (FDA) pregnancy risk categories are as follows: A,
no risk in controlled clinical studies in humans; B, human data reassuring or when absent, animal studies show no risk; C, human data are lacking;
animal studies show risk or are not done; D, positive evidence of risk, benefit may outweigh; X, contraindicated during pregnancy. bAccumulated
experience indicates that azathioprine can be used throughout pregnancy without increase in congenital abnormalities.
neutropenia in an infant whose mother was taking 3 g of SSZ
daily throughout pregnancy [119].
Breastfeeding
Insignificant amounts of uncleaved SSZ have been found in
milk, whereas the sulphapyridine levels in milk were about 30
to 60% of those in maternal serum [120]. Diarrhoea and rash
were reported in a breastfed infant whose mother was
receiving SSZ [121]. Exposure to sulphonamides through
breast milk apparently does not pose a significant risk for the
healthy, full-term newborn infant, but it should be avoided in
ill, stressed or premature infants and in infants with hyper-
bilirubinaemia or glucose-6-phosphate dehydrogenase
deficiency [43].
Fertility
SSZ does not impair fertility in women. Treatment with SSZ
leads to oligospermia, reduced sperm motility, an increased
proportion of abnormal forms, and infertility in men and rats
[122]. The effect is due to sulphapyridine and cannot be
abrogated by folate supplementation. Spermatogenesis
recovers at about 2 months after withdrawal of the drug [122].
Conclusion and recommendation (Tables 3 and 4)
• Continuation of SSZ during pregnancy is unlikely to cause
fetal harm (evidence level II).
• Folate supplementation is necessary before and through-
out pregnancy (evidence level I).
• To prevent neutropenia in the newborn infant, maternal
doses of SSZ should not exceed 2 g daily (evidence level
IV).
• Male infertility caused by SSZ recovers after dis-
continuation of the drug. Men should stop SSZ 3 months
before attempting to father a child (evidence level IV).
• Breastfeeding is allowed in the healthy, full-term infant
(evidence level IV).
Leflunomide
Potential mutagenic and teratogenic effect
Leflunomide given to pregnant rats and rabbits in doses
equivalent to human doses induced malformations of the
skeleton and central nervous system in the offspring. Prenatal
exposure to about 1% of the human dose resulted in
decreased birthweight and increased perinatal mortality in the
offspring [123].
Available online http://arthritis-research.com/content/8/3/209
Page 9 of 19
(page number not for citation purposes)
Table 4
Immunosuppressive, cytotoxic and biological drugs during lactation
Drug Secretion into breast milk Effect on nursing infant Breastfeeding allowed
Chloroquine 0.55% of maternal dose [100,102] No adverse effects Compatible with breastfeeding
Hydroxychloroquine 0.35% of maternal dose [103,104] No adverse effects Compatible with breastfeeding
Sulphasalazine Sulphasalazine and sulphapyridine Well tolerated, 1 case of bloody Allowed in the healthy full-term infant
secreted at 5.9% of maternal diarrhoea [121]
dose [120]
Leflunomide No data published No data published Avoid because of theoretical risk
Azathioprine (AZA)/ AZA and its metabolites detected 9 children nursed (AZA) without Avoid because of theoretical risk
6-mercaptopurine (6-MP) in milk [135] adverse effects, 1 child (6-MP) well
Methotrexate Excreted in low concentrations. Not known Avoid because of theoretical risk
Milk:plasma ratio of 0.08 [155]
Cyclophosphamide Secreted (amount unknown) [172] Suppression of haematopoiesis Contraindicated during lactation
reported in one nursing child [169]
Cyclosporine Milk:plasma concentration < 1; No adverse effects observed in No consensus, weigh risk/benefit
wide variability in drug 9 breastfed children [188]
disposition [188]
Tacrolimus Minute amounts secreted, 1 child nursed without side Breastfeeding probably possible
nursing infant exposed to 0.06% effects [197]
of mother’s dose [197]
Mycophenolate mofetil No human studies Not known Avoid because of theoretical risk
Intravenous No data published Not known Breastfeeding probably possible
immunoglobulin
Etanercept Secreted at 0.04% of maternal Not known Data inconclusive, weigh risk/benefit
dose [207]
Infliximab Secreted in small amount [211] Not known Avoid because of theoretical risk
In a retrospective study, 10 pregnancies occurred in RA
patients treated with leflunomide. No congenital malformation
occurred in the five pregnancies with known outcome [124].
An unpublished safety update of the manufacturer in
September 2004 reported 428 exposures during pregnancy,
with known outcome for 165 pregnancies. Twenty-one
pregnancies occurred while the male partner was receiving
leflunomide. Termination was performed in 44 cases,
miscarriage occurred in 36 cases and 85 pregnancies went
to term. Congenital malformations occurred in seven children.
A Canadian prospective cohort study is currently in progress
to investigate possible fetal and neonatal side effects of
leflunomide exposure during pregnancy. At present, the study
includes a total of 246 pregnancies with known outcome. No
significant differences between exposed and non-exposed
pregnancies were noted with regard to spontaneous abortion
or major structural defects in newborn infants.
Conclusions and recommendations (Tables 3 and 4)
• Leflunomide is contraindicated during pregnancy. Safe
contraception during therapy in both women and men is
recommended by the manufacturer (evidence level IV).
• When a pregnancy is being planned, leflunomide must be
withdrawn. Because the active metabolite of leflunomide
is detectable in plasma until 2 years after discontinuation
of the drug, cholestyramine must be given to enhance
elimination from the body until plasma levels of lefluno-
mide are undetectable (evidence level IV).
• No data exist on excretion into breast milk; breastfeeding
is therefore not recommended (evidence level IV).
Azathioprine and 6-mercaptopurine (6-MP)
Azathioprine is a prodrug that after absorption is cleaved to
6-MP, its active metabolite.
Potential mutagenic and teratogenic effect
The fetal liver lacks the enzyme inosinatopyrophosphorylase,
which converts azathioprine to its active form and therefore
should be theoretically protected from azathioprine crossing
the placenta [125].
Azathioprine injected intraperitoneally in doses equivalent to
4 to 13 times the therapeutic human dose caused skeletal
defects and multiple malformations in mice and rabbits
exposed during gestation [125]. In rodents exposed in utero
to 1 to 62.5 times the human dose of 6-MP, cleft palate,
dilatation of cerebral ventricles and hydrocephalus were
observed. Female and male offspring of mice receiving 6-MP
in pregnancy had a decreased number of germ cells in the
gonads, with resulting decreased fertility [126].
Studies in pregnant transplant recipients receiving
azathioprine and prednisone and in pregnant patients treated
for IBD with azathioprine or 6MP showed no increase in
pregnancy complications or congenital malformations [127-
129]. Intrauterine growth restriction has been reported in
40% of renal graft recipient mothers taking both cortico-
steroids and azathioprine [64]. Anecdotal experience has
associated prenatal exposure to azathioprine with different
congenital anomalies, but none of them were clearly linked to
the drug. Other reported events after antenatal exposure to
azathioprine were transient chromosomal anomalies in
clinically normal infants [130], transient lymphopenia
[130,131], severe immune deficiency and cytomegalovirus
infection [131], and depressed haematopoiesis in infants
whose mothers were treated with more than 2 mg/kg
azathioprine daily [132].
One group reported an increased incidence of spontaneous
abortions and congenital malformations in pregnancies
fathered by 13 men treated with 6-MP for IBD at conception
or in the 3 months previously [133]. However, it is uncertain
whether the control group of untreated IBD male patients
was comparable. In addition the overall rate of congenital
malformations was within the baseline incidence. Another
study did not find any increase in adverse outcomes in men
and women treated for IBD with 6-MP before or during the
first trimester [134].
Breastfeeding
Azathioprine and its metabolites were found in milk, exposing
the child to 0.1% of the maternal dose [135]. Nine children
were nursed without side effects.
Fertility
Azathioprine does not adversely affect the fertility of women.
A recent study in men found semen quality and quantity to be
normal despite long-term treatment with azathioprine [136].
Long-term effects in offspring
Postnatal enhancement of T cell maturation, but otherwise
normal immunological development, was detected in
children exposed to azathioprine in utero [137]. A recent
case report found the development of autoimmunity in a
daughter of a patient with SLE who had received
azathioprine during pregnancy and regarded this as a
possible long-term effect of exposure in utero [138].
However, a genetic predisposition as the cause of the
daughter’s SLE cannot be ruled out.
Conclusion and recommendations (Tables 3 and 4)
• When indicated, azathioprine can be used during
pregnancy at a daily dose not exceeding 2 mg/kg per day
(evidence level II).
• There is no consensus on the use of 6-MP, the active
metabolite of azathioprine during pregnancy. Some
experts recommend the avoidance of its use during
pregnancy (evidence level IV).
• No consensus on nursing exists among experts. The AAP
does not recommend breastfeeding because of the
theoretical risk of immunosuppression, carcinogenesis
and growth restriction in the child (evidence level IV).
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Methotrexate (MTX)
Potential mutagenic and teratogenic effect
MTX is a methyl derivative of the folate antagonist
aminopterin. Active metabolites of MTX remain in cells or
tissues for several months after the cessation of therapy
[139]. Closure of the neural tube takes place during week 5;
the embryo is therefore probably most vulnerable to anti-
folate drugs at this time. The congenital anomalies observed
in animals and humans exposed to MTX in utero usually
involved the central nervous system, cranial ossification, the
limbs and the palate and growth retardation [140-142].
Experience with MTX in human pregnancy has been derived
mainly from patients treated for cancer with multiagent
therapy or when MTX or aminopterin was used unsuccess-
fully as an abortifacient to terminate a pregnancy [143,144].
In most of these reports, doses of MTX exceeded the low-
dose weekly pulses (5 to 20 mg) applied in rheumatology.
Three infants exposed to MTX during the first trimester had
multiple cranial anomalies [143-145]. Chromosomal aberra-
tions were detected in a healthy newborn infant exposed to
MTX and other cytotoxic drugs during pregnancy [144]. In
seven cases, MTX had been given during the second and
third trimester; six normal children were born and one child
had pancytopenia [145].
Reviewing the rheumatology literature of first-trimester
exposure to once-weekly doses of 20 mg of MTX or less,
disclosed 63 pregnancies [124,146-151]. In the pregnancies
not terminated electively, 11 (17%) ended in miscarriage, and
of the 33 that proceeded to delivery, four children (12%) had
congenital anomalies, including one child with multiple
skeletal abnormalities [149]. Birthweights of the full-term
infants were within normal range. Previous treatment of
women with MTX has no harmful effect on subsequent
pregnancy outcomes [152,153]. So far there are no reports
of adverse pregnancy outcomes among men exposed to MTX
before conception [154].
Breastfeeding
MTX is excreted into breast milk in low concentrations, with a
milk:plasma ratio of 0.08 [155]. The significance of this small
amount for the nursing child is unknown.
Fertility
MTX does not impair female fertility. There is no indication
that monotherapy with MTX induces infertility in men [156],
although a case report has described oligospermia in a male
patient treated with MTX for psoriasis [157].
Long-term effects in children
A follow-up study of children exposed antenatally to cytotoxic
drugs including MTX showed physical, neurological,
psychological, haematological, immune function and
cytogenetics to be normal after 3 to 19 years [158]. A follow-
up ranging from 0.1 to 16.7 years of an additional seven
children revealed no developmental or other serious health
problems [146].
Conclusions and recommendations (Tables 3 and 4)
• MTX is contraindicated during pregnancy and should be
prescribed to fertile women only under the cover of safe
contraception (evidence level III).
• MTX must be withdrawn prophylactically 3 months before
a planned pregnancy (evidence level IV).
• Folate supplementation should be continued antenatally
and throughout pregnancy (evidence level I).
• It is not known whether once-weekly administration of
MTX has any significance for the nursing child, given the
minute amounts excreted into breast milk. The AAP does
not recommend breastfeeding because of theoretical
risks (evidence level IV).
Cyclophosphamide (CYC)
Potential mutagenic and teratogenic effect
CYC is teratogenic in all animal species studied, including
mice, rats, rabbits and monkeys [159]. Abnormalities induced
in animals by specific dose ranges and at specific periods of
gestation showed a rather consistent pattern of brain
malformation, defective limbs and facial abnormalities.
CYC has an unpredictable effect on the human fetus
because it does not always cause malformations when given
during the first trimester [160-163]. CYC embryopathy has
been reported in nine cases, including defects of the calvaria,
anomalies of craniofacial structures, ears and limbs, visceral
organs, growth retardation and developmental delay during
childhood [160-168]. CYC given in the second and third
trimester does not result in structural abnormalities but it may
cause growth restriction, impair neurological development
and suppress haematopoiesis in the infant [164,169].
Therapy with CYC completed before pregnancy does not
increase the rate of miscarriage or congenital abnormalities in
offspring [170].
Little information is available about the outcome of children
born to men taking CYC. Isolated reports of congenital
abnormalities have been associated with paternal use of
CYC, but a direct relationship is difficult to prove [171].
Breastfeeding
CYC is excreted into human breast milk [172]. Suppression
of haematopoiesis has been reported in a breastfed infant
nursed by a mother who received CYC [169].
Fertility
CYC is gonadotoxic in both women and men, depending on
the cumulative dose and the age of the patient. Impairment of
fertility follows both daily oral and intermittent pulse therapy
[173]. In women, sustained amenorrhoea after a total dose of
3.5 to 7 g of CYC was rare under the age of 25 years,
increased to 12% for patients aged 26 to 30 years and to
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25% for patients aged 31 years or older [174]. Women older
than 32 years have a substantial risk for amenorrhoea at
8 g/m2, which increases to sustained amenorrhoea for 90%
of women at 12 g/m2 [175]. In men, gonadotoxicity of CYC is
present even before puberty [176]. There is no safe threshold
of the cumulative dose, and it is not possible to predict which
patients will become sterile and which will recover testicular
function [177].
Preservation of gonadal function during CYC therapy in
women is best done by concomitant treatment with a
gonadotrophin-releasing hormone agonist, as a case-control
study has shown [178]. Cryopreservation of sperm and
sperm banking is the method of choice in men who have no
children or have not completed their families.
Long-term effects in children
A case of a papillary thyroid cancer at the age of 11 years
and a neuroblastoma at age 14 years in a male twin exposed
to CYC in utero has been reported. The female twin was
unaffected [164]. A population-based study did not find any
increase in chromosomal abnormalities in offspring of
childhood cancer survivors in Denmark treated with cytotoxic
drugs including CYC, nor an increase in Down syndrome or
Turner syndrome [179].
Conclusion and recommendation (Tables 3 and 4)
• CYC is a human teratogen (evidence level III).
• CYC is gonadotoxic in men and women (II).
• Intravenous CYC therapy should be started only after a
negative pregnancy test (evidence level IV).
• Measures for preservation of fertility must be taken
(evidence level IV).
• Safe contraception is necessary when fertile women are
treated with CYC (evidence level IV).
• Attempts at conception should be delayed until 3 months
after the cessation of therapy (evidence level IV).
• Breastfeeding is not recommended (evidence level IV).
Cyclosporin A (CsA)
Potential mutagenic and teratogenic effect
CsA was not toxic to the exposed fetuses at the maternal
dosage of 10 mg/kg per day, whereas it was embryotoxic at
dosages of 25 to 100 mg/kg per day [180].
More than 800 pregnancies receiving CsA have been
reported, mainly in transplant recipients [181-185]. The
observed rate of 3% of congenital malformations has not
exceeded the rate reported in the general population, nor has
any particular pattern of abnormalities emerged. Renal and
liver function were normal in 166 newborn infants exposed to
CsA in utero [186]. A meta-analysis evaluated the risk of
congenital malformations, preterm delivery or low birthweight
from CsA treatment during pregnancy [187]. The calculated
OR of 3.83 for malformations did not achieve statistical
significance. The overall prevalence of 4.1% of malformations
in the study population did not vary substantially from that
reported in the general population. The OR for prematurity
did not reach statistical significance, although the overall
prevalence rate was 56.3%. It is not clear whether maternal
therapy with CsA or the underlying maternal disease was
associated with increased rates of prematurity and low
birthweight (less than 2,500 g).
Breastfeeding
Small amounts of CsA are excreted in breast milk. Successful
breastfeeding without side effects has been reported in 15
children [188].
Long-term follow-up of children
Follow-up for 1 to 12 years of 175 children registered in the
National Transplantation Pregnancy Register (USA) found
normal development in 84% of offspring exposed to CsA in
utero [189]. The high incidence of prematurity was
suspected to be involved in the mental developmental delay
observed in 16% of the children. Because CsA can induce
autoimmunity in rodents after exposure in utero, several
studies have addressed this issue in children of transplant
recipients. The maturation and development of T cells, B cells
and NK cells can be impaired during the first year of life
[137], and transient B cell depletion has been described in
several infants [190]. A case-control study of the immune
function of children born to mothers with connective tissue
diseases found normal blood cell counts, immunoglobulin
levels and lymphocyte subpopulations in offspring of mothers
treated with immunosuppressive drugs (including CsA)
[191]. All children responded satisfactorily to hepatitis B
vaccination. A paediatric follow-up ranging from 3 months to
11 years of age found three cases with long-term develop-
mental difficulties, but no learning disability (mental
retardation) among 31 children exposed to CsA during
pregnancy [192].
Conclusion and recommendation (Tables 3 and 4)
• CsA can be maintained in pregnancy at the lowest
effective dose (evidence level I).
• Control maternal blood pressure and renal function during
therapy (evidence level II).
• There is no consensus among experts on nursing. Safety
during breastfeeding is not proven (evidence level IV). The
AAP does not recommend breastfeeding because of
theoretical risks.
Tacrolimus
Potential mutagenic and teratogenic effect
Tacrolimus is fetotoxic in animals, causing increased late fetal
loss and decreased live birth rate.
No controlled human studies are available. Two studies from
the same centre, one retrospective, the other prospective,
examined the outcome of a total of 70 pregnancies under
tacrolimus after kidney transplantation, simultaneous kidney–
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pancreas transplantation, or liver transplantation [193,194].
About 50% of the babies were either preterm or premature;
one was born with congenital anomalies [194].
A retrospective analysis recorded 100 pregnancies in 84
mothers treated with a mean daily dose of tacrolimus of
12 mg/day during 1992 to 1998 [195]. Of the pregnancies
with known outcome, 71 progressed to delivery (68 live
births, 2 neonatal deaths and 1 stillbirth) and 24 were
terminated (12 spontaneous and 12 induced). The mean
duration of gestation was 35 weeks, with 59% of deliveries
being premature, but with appropriate birthweight in 90% of
cases. The most common complications in the newborn
infant were transient hypoxia, hyperkalaemia and renal
dysfunction. Four newborn infants presented with malforma-
tions, without any consistent pattern of affected organs. An
additional study found no increase in congenital anomalies in
newborn infants born to tacrolimus-treated kidney recipients
[196].
Breastfeeding
According to one case report, only 0.02% of the mother’s
dose of tacrolimus is transmitted to the breastfed baby [197].
Conclusion and recommendation (Tables 3 and 4)
• Tacrolimus may be maintained during pregnancy at the
lowest possible dose (evidence level III).
• Breastfeeding is possible (evidence level IV).
Mycophenolate mofetil (MMF)
Potential mutagenic and teratogenic effect
Treatment of pregnant rats and rabbits with 30 to 50% of the
human dose has resulted in birth defects in the offspring,
comprising the central nervous system, cardiovascular and
renal system [198].
No controlled studies on pregnancy during treatment with
MMF are available, but data exist in drug company files
(Roche Pharma, safety update). By April 2005, 119
pregnancies under maternal treatment with MMF had been
reported; however, the outcome is known for only 76 of
these. Twenty miscarriages and 13 terminations of pregnancy
were reported. Twenty-two deliveries resulted in healthy
newborn infants. Abnormalities at birth were observed in 10
newborn infants, yet a causative role for MMF could not be
established. Sixty-nine pregnancies occurred after paternal
exposure, with a known outcome for 45 of these. Six
congenital anomalies such as foot malformation, hand
malformation, bladder anomaly and chromosomal abnormality
were reported; 36 newborn infants were healthy.
Two newborn infants with structural congenital anomalies
were reported from the National Transplantation Pregnancy
Registry after in utero exposure to MMF [199,200]. One child
had hypoplastic nails and short fifth fingers, normal
chromosomes, and normal growth and development [199]. A
terminated pregnancy of a patient treated with MMF before
conception and during the first trimester of pregnancy
disclosed multiple fetal malformations, specifically facial
dysmorphology and midline anomalies, including agenesis of
the corpus callosum [198].
Conclusion and recommendation (Tables 3 and 4)
• MMF is contraindicated during pregnancy and should be
given to women of fertile years only under cover of reliable
contraception (evidence level III).
• Because of enterohepatic recirculation and a long half-
life, treatment with MMF should be stopped at least
6 weeks before a planned pregnancy (evidence level IV).
• No data exist on excretion into breast milk; breastfeeding
is therefore not recommended (evidence level IV).
Intravenous immunoglobulin
Placental transfer of IgG is dependent on the dose and
gestational age. It crosses the placenta in significant
amounts after 32 weeks of gestation. Studies on pregnant
patients with haematological and autoimmune diseases have
focused on fetal survival but not on neonatal health. No fetal
adverse effects of intravenous immunoglobulin have been
reported. Randomized trials with regard to immune function
in the newborn infant or in response to vaccination in
childhood have not been performed. Normal percentages of
T cells, B cells, NK cells and monocytes were found in 20
infants born after maternal immunoglobulin treatment for fetal
alloimmune thrombocytopenia [201]. No data are available
with regard to fertility or breastfeeding, but harmful effects
seem unlikely.
Conclusion and recommendation (Tables 3 and 4)
• Intravenous immunoglobulin can be used in pregnancy
(evidence level II).
• Breastfeeding is allowed (evidence level IV).
Biological drugs
At the present stage of knowledge, there is no evidence
implicating tumour necrosis factor-α antagonists with
embryotoxicity, teratogenicity or increased pregnancy loss
(Table 3). Except for a few case reports on successful
pregnancies [202-205], no data on fertility or breastfeeding
are available for adalimumab (human monoclonal antibody
against TNF-α), anakinra (the interleukin-1 receptor antago-
nist) or rituximab (the monoclonal antibody against CD20).
For the latter drugs no recommendations with regard to
reproduction are given.
Etanercept
Potential mutagenic and teratogenic effect
Soluble TNF-R crosses the placenta and gains access to the
fetal circulation in mice but does not interrupt pregnancy or
impair fetal development. Pregnancy studies in rats and
rabbits using 60 to 100 times the human dose of etanercept
did not show any teratogenicity or fetotoxicity [206].
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Experience from 32 pregnancies treated with etanercept has
been reported without an increased risk of congenital
abnormalities or other adverse effects [124,207].
Breastfeeding
A case report showed that etanercept is excreted into human
breast milk. The effect on the nursing child is not known
[208].
Conclusion and recommendation (Tables 3 and 4)
• Etanercept should not be continued during pregnancy
because of a lack of much information (evidence level IV).
• Because the effect on the nursing child is not known,
breastfeeding is not recommended (evidence level IV).
Infliximab
Potential mutagenic and teratogenic effect
A developmental toxicity study conducted in mice using an
analogous murine anti-TNF-α antibody showed no evidence
of maternal toxicity, embryotoxicity, or teratogenicity [209].
Several case reports and small series have reported an
absence of adverse fetal or maternal outcomes after
treatment with infliximab during pregnancy [124,207,210].
Data from the infliximab safety database, including 146
pregnancies of women affected by Crohn’s disease and
rheumatoid arthritis collected from October 1998 to April
2003, found that 131 pregnant women were exposed directly
to the drug, 15 indirectly through their partners [211].
Outcome data were available for 106 of these patients. Live
births occurred in 67% (64 of 96), miscarriages in 15% (14
of 96), and therapeutic termination in 19% (18 of 96) of the
pregnancies. The study suggests that infliximab exposure
during pregnancy results in outcomes that do not differ from
those in the United States population of pregnant women
with or without Crohn’s disease not exposed to the drug.
Breastfeeding
Passage of infliximab into human breast milk in one patient
with RA was demonstrated [212].
Fertility
Semen quality was studied in eight men receiving infliximab
for IBD [213]. Semen samples showed no statistical
difference between pre-infusion and post-infusion values.
Motility and the percentage of normal oval forms were below
normal both before and after infusion, probably reflecting the
underlying disease process or previous therapy. The results
of the study suggest that semen quality is not seriously
affected by infliximab treatment.
Conclusion and recommendation (Tables 3 and 4)
• The safety of infliximab during pregnancy has not been
sufficiently documented (evidence level III). It should
therefore be stopped when pregnancy is recognized
(evidence level IV).
• Because the effect on the nursing child is not known,
breastfeeding is not recommended (evidence level IV).
Conclusion
In an area in which controlled studies are lacking for the most
part, uncertainty about the magnitude of risk demands a
cautious approach to the therapy of pregnant and lactating
women. Data accumulate slowly and in an uncontrolled way
regarding immunosuppressive drugs and pregnancy.
Information continues to be insufficient with regard to
lactation, to gonadotoxic effects, and to long-term effects in
children exposed to immunosuppressive drugs in utero or by
breastfeeding. Studies of these issues are urgently needed.
The updating of available information at regular intervals and
adjustment of recommendations on the use of drugs during
pregnancy and lactation is warranted.
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